Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims at evaluating efficacy and safety of Symbicort® Turbuhaler® in Chinese COPD patients as defined by GOLD treatment guidelines in order to obtain an approval for indication of COPD from Chinese State Food and Drug Administration.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Formoterol Fumarate; Terbutaline

Criteria

Inclusion Criteria:

• Signed and dated inform consent

• Out-patient, clinical diagnosis of COPD

• Men or women at the age of 40 or over

Exclusion Criteria:

• A history of asthma

• Seasonal allergic rhinitis before 40 years of age

• Patients with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator or other disorder